BTIG analyst Thomas Catherwood downgrades Paramount Group (NYSE:PGRE) from Buy to Neutral.
Needham Maintains Buy on Pacira BioSciences, Lowers Price Target to $60
Needham analyst Serge Belanger maintains Pacira BioSciences (NASDAQ:PCRX) with a Buy and lowers the price target from $63 to $60.